Literature DB >> 15530610

New therapeutic targets in multiple myeloma.

Gösta Gahrton1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15530610     DOI： 10.1016/S0140-6736(04)17371-6

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  5 in total

1.  Differential downregulation of telomerase activity by bortezomib in multiple myeloma cells-multiple regulatory pathways in vitro and ex vivo.

Authors:  C Weiss; O Uziel; O Wolach; J Nordenberg; E Beery; S Bulvick; G Kanfer; O Cohen; R Ram; M Bakhanashvili; H Magen-Nativ; N Shilo; M Lahav
Journal:  Br J Cancer       Date:  2012-11-20       Impact factor: 7.640

2.  Bone marrow-derived mesenchymal stem cells inhibit CD8+ T cell immune responses via PD-1/PD-L1 pathway in multiple myeloma.

Authors:  Z Liu; F Mi; M Han; M Tian; L Deng; N Meng; J Luo; R Fu
Journal:  Clin Exp Immunol       Date:  2021-05-07       Impact factor: 5.732

3.  The Analysis of the Relationship between Multiple Myeloma Cells and Their Microenvironment.

Authors:  Artur Jurczyszyn; Jacek Czepiel; Joanna Gdula-Argasińska; William Perucki; Aleksander B Skotnicki; Marcin Majka
Journal:  J Cancer       Date:  2015-01-05       Impact factor: 4.207

4.  Geldanamycin and Its Derivatives Inhibit the Growth of Myeloma Cells and Reduce the Expression of the MET Receptor.

Authors:  Artur Jurczyszyn; Anna Zebzda; Jacek Czepiel; William Perucki; Stanisława Bazan-Socha; Dorota Cibor; Danuta Owczarek; Marcin Majka
Journal:  J Cancer       Date:  2014-05-31       Impact factor: 4.207

5.  The KISS1 Receptor as an In Vivo Microenvironment Imaging Biomarker of Multiple Myeloma Bone Disease.

Authors:  Julia Dotterweich; Robert J Tower; Andreas Brandl; Marc Müller; Lorenz C Hofbauer; Andreas Beilhack; Regina Ebert; Claus C Glüer; Sanjay Tiwari; Norbert Schütze; Franz Jakob
Journal:  PLoS One       Date:  2016-05-09       Impact factor: 3.240
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.